Simcere Pharmaceutical Group Management
Management criteria checks 2/4
Simcere Pharmaceutical Group's CEO is Jinsheng Ren, appointed in Mar 1995, has a tenure of 29.75 years. total yearly compensation is CN¥7.43M, comprised of 67.6% salary and 32.4% bonuses, including company stock and options. directly owns 4.98% of the company’s shares, worth €103.82M. The average tenure of the management team and the board of directors is 1.9 years and 5.1 years respectively.
Key information
Jinsheng Ren
Chief executive officer
CN¥7.4m
Total compensation
| CEO salary percentage | 67.6% |
| CEO tenure | 29.8yrs |
| CEO ownership | 5.0% |
| Management average tenure | 1.9yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥1b |
| Mar 31 2024 | n/a | n/a | -CN¥194m |
| Dec 31 2023 | CN¥7m | CN¥5m | CN¥715m |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥2b |
| Dec 31 2022 | CN¥3m | CN¥2m | CN¥931m |
| Sep 30 2022 | n/a | n/a | CN¥972m |
| Jun 30 2022 | n/a | n/a | CN¥1b |
| Mar 31 2022 | n/a | n/a | CN¥1b |
| Dec 31 2021 | CN¥2m | CN¥2m | CN¥2b |
| Sep 30 2021 | n/a | n/a | CN¥1b |
| Jun 30 2021 | n/a | n/a | CN¥1b |
| Mar 31 2021 | n/a | n/a | CN¥856m |
| Dec 31 2020 | CN¥2m | CN¥1m | CN¥670m |
| Sep 30 2020 | n/a | n/a | CN¥699m |
| Jun 30 2020 | n/a | n/a | CN¥728m |
| Mar 31 2020 | n/a | n/a | CN¥866m |
| Dec 31 2019 | CN¥2m | CN¥1m | CN¥1b |
Compensation vs Market: Jinsheng's total compensation ($USD1.02M) is below average for companies of similar size in the German market ($USD1.52M).
Compensation vs Earnings: Jinsheng's compensation has increased whilst the company is unprofitable.
CEO
Jinsheng Ren (62 yo)
29.8yrs
Tenure
CN¥7,426,000
Compensation
Mr. Jinsheng Ren founded Simcere Pharmaceutical Group Limited in March 1995 and its Chairman since 2023 and serves as its Director and also serves as its Chief Executive Officer since November 19, 2019 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 29.8yrs | CN¥7.43m | 4.98% € 103.8m | |
| CFO, Joint Company Secretary & Executive Director | 2.1yrs | CN¥9.36m | 0.049% € 1.0m | |
| Executive Director | 1.9yrs | CN¥14.53m | 0.062% € 1.3m | |
| VP & Executive Director | 1.9yrs | CN¥1.33m | no data | |
| CFO & Secretary of the Board of Simcere Zaiming | less than a year | no data | no data | |
| Chief Investment Officer | 1.9yrs | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Senior VP & Chief Scientific Officer of Simcere Zaiming | 2.3yrs | no data | no data | |
| Senior VP & Chief Medical Officer | less than a year | no data | no data | |
| Senior Vice President | less than a year | no data | no data | |
| Senior VP & Chief Medical Officer of Simcere Zaiming | less than a year | no data | no data | |
| Senior VP & Secretary of the Party Committee | less than a year | no data | no data |
1.9yrs
Average Tenure
51.5yo
Average Age
Experienced Management: S2P's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.1yrs | CN¥7.43m | 4.98% € 103.8m | |
| CFO, Joint Company Secretary & Executive Director | 5.1yrs | CN¥9.36m | 0.049% € 1.0m | |
| Executive Director | 5.1yrs | CN¥14.53m | 0.062% € 1.3m | |
| VP & Executive Director | 1.9yrs | CN¥1.33m | no data | |
| Independent Non-Executive Director | 5.1yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 5.1yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 5.1yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 1.9yrs | CN¥360.00k | no data |
5.1yrs
Average Tenure
57.5yo
Average Age
Experienced Board: S2P's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 10:57 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Simcere Pharmaceutical Group Limited is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Shaojing Tong | BofA Global Research |
| Bo Yu | China International Capital Corporation Limited |